[CAS NO. 2762422-55-7] AC1-IN-1
PRODUCTS SPECIFICATIONS [2762422-55-7]
DESCRIPTION [2762422-55-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 355.37 |
| Molecular Formula | C18H18FN5O2 |
| SMILES | CCC1=CC(NC(N2N=C(C=C2NC(C3=C(C=CC(C)=C3)F)=O)C)=N1)=O |
Summary
AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC 50 of 0.54 µM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity [1] .
IC50 & Target
IC 50 : 0.54 µM (AC1) [1]
In Vitro
AC1-IN-1 (compound 38; HEK293 cells; 30 µM, 1 hours) shows nontoxic to this human cell line [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay [1]
| Cell Line: | HEK293 cells |
| Concentration: | 30 µM |
| Incubation Time: | 1 hours |
| Result: | Showed nontoxic to HEK293 cells. |
In Vivo
AC1-IN-1 (5.6 mg/kg; i.v.) displays modest, yet statistically significant, antiallodynic effects at 1 h post-treatment compared to the 0 min (allodynic) time point [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male and female C57BL/6N mice (complete Freund’s adjuvant inflammatory pain model) [1] |
| Dosage: | 5.6 mg/kg (dissolved in 10% DMSO/10% Cremaphor/80% saline) |
| Administration: | Intravenous injection; 2 hours |
| Result: | Displayed modest, yet statistically significant, antiallodynic effects. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 70.35 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8140 mL | 14.0698 mL | 28.1397 mL |
| 5 mM | 0.5628 mL | 2.8140 mL | 5.6279 mL |
| 10 mM | 0.2814 mL | 1.4070 mL | 2.8140 mL |